Contact
searchSearch
HMP Global
Login

Digital Therapeutics Topic Center

FDA approval stamp
News
FDA Approves First Prescription Digital Therapeutic for Adjunctive Major Depressive Disorder Treatment
04/30/2024
Meagan Thistle
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as...
04/30/2024
Psych Congress Network
Brain Training Aids Overall Cognitive Ability in Adults With ADHD
News
Brain Training Aids Overall Cognitive Ability in Adults With ADHD
10/02/2023
Jolynn Tumolo
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training...
10/02/2023
Psych Congress Network
digital brain
News
Digital Therapeutic Eases Experiential Negative Symptoms in Patients with Schizophrenia
09/09/2023
Jolynn Tumolo
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription...
09/09/2023
Psych Congress Network
talking with psychiatrist
News
Wrist-wearable Device Biomarkers May Help Predict Adverse Posttraumatic Neuropsychiatric Symptoms
01/23/2023
Meagan Thistle
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers...
01/23/2023
Psych Congress Network
News
Virtual Reality-Based Treatment Shows No Effect on Social Cognition in Patients With Schizophrenia
01/10/2023
Evi Arthur
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR,...
01/10/2023
Psych Congress Network
News
Prenatal Depression Screening, Referral Improves After Online Provider Training
01/02/2023
Jolynn Tumolo
Screening for prenatal depression and referral for care increased after providers underwent a brief online training intervention, study says.
Screening for prenatal depression and referral for care increased after providers underwent a brief online training intervention, study says.
Screening for prenatal...
01/02/2023
Psych Congress Network
News
Online Pain Programs Reduce Anxiety, Depressive Symptoms in People With Chronic Pain
12/26/2022
Jolynn Tumolo
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management...
12/26/2022
Psych Congress Network
Dr Steven Chan at Psych Congress Elevate
Videos
Telehealth Chatbots Promising, but Need Further Research
11/08/2022
Steven Chan, MD, MBA
Steven Chan, MD, MBA, talks research that supports or challenges mental health apps in clinical practice.
Steven Chan, MD, MBA, talks research that supports or challenges mental health apps in clinical practice.
Steven Chan, MD, MBA, talks...
11/08/2022
Psych Congress Network
News
FDA Clears Neuromodulation System for Patients With MDD
09/19/2022
Jolynn Tumolo
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug...
09/19/2022
Psych Congress Network
News
At-Home Transcranial Direct Current Stimulation Helps Attention in Adults with ADHD
08/09/2022
Jolynn Tumolo
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based...
08/09/2022
Psych Congress Network
Dr Steven Chan
Videos
Assess Features and Set Realistic Expectations When Choosing and Using Apps in Clinical Practice
08/08/2022
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses...
08/08/2022
Psych Congress Network

News

FDA approval stamp
News
FDA Approves First Prescription Digital Therapeutic for Adjunctive Major Depressive Disorder Treatment
04/30/2024
Meagan Thistle
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as...
04/30/2024
Psych Congress Network
Brain Training Aids Overall Cognitive Ability in Adults With ADHD
News
Brain Training Aids Overall Cognitive Ability in Adults With ADHD
10/02/2023
Jolynn Tumolo
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training...
10/02/2023
Psych Congress Network
digital brain
News
Digital Therapeutic Eases Experiential Negative Symptoms in Patients with Schizophrenia
09/09/2023
Jolynn Tumolo
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription...
09/09/2023
Psych Congress Network
talking with psychiatrist
News
Wrist-wearable Device Biomarkers May Help Predict Adverse Posttraumatic Neuropsychiatric Symptoms
01/23/2023
Meagan Thistle
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers may be useful screening tools for pain, sleep, and anxiety symptom treatment outcomes after trauma exposure.
Wrist-wearable device biomarkers...
01/23/2023
Psych Congress Network
News
Virtual Reality-Based Treatment Shows No Effect on Social Cognition in Patients With Schizophrenia
01/10/2023
Evi Arthur
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR,...
01/10/2023
Psych Congress Network
News
Prenatal Depression Screening, Referral Improves After Online Provider Training
01/02/2023
Jolynn Tumolo
Screening for prenatal depression and referral for care increased after providers underwent a brief online training intervention, study says.
Screening for prenatal depression and referral for care increased after providers underwent a brief online training intervention, study says.
Screening for prenatal...
01/02/2023
Psych Congress Network
News
Online Pain Programs Reduce Anxiety, Depressive Symptoms in People With Chronic Pain
12/26/2022
Jolynn Tumolo
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management...
12/26/2022
Psych Congress Network
News
FDA Clears Neuromodulation System for Patients With MDD
09/19/2022
Jolynn Tumolo
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug...
09/19/2022
Psych Congress Network
News
At-Home Transcranial Direct Current Stimulation Helps Attention in Adults with ADHD
08/09/2022
Jolynn Tumolo
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based...
08/09/2022
Psych Congress Network
News
FDA Grants Breakthrough Device Designation to Investigate Deep Brain Stimulation System in TRD
08/04/2022
Jolynn Tumolo
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott...
08/04/2022
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
An illustration of a brain
News
Disease Duration, Antipsychotic Use, and Brain Aging in Schizophrenia
01/06/2026
Sarah Fleming
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in...
01/06/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
a group of clinicians
News
Collaborative Care Shows No Added Benefit for OUD With Depression or PTSD
01/02/2026
Maria Mantas
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model...
01/02/2026
Psych Congress Network
A woman with insomnia lying in bed trying to sleep
News
Sleep and Psychiatric Disorders: Shared Mechanisms and Clinical Relevance
01/02/2026
Sarah Fleming
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS...
01/02/2026
Psych Congress Network
A person's hands typing on a smartphone
News
Smartphone-Delivered Digital CBT Improves Anxiety Symptoms in Adults
12/29/2025
Sarah Fleming
A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
A smartphone-delivered digital...
12/29/2025
Psych Congress Network

Insights

Dr Steven Chan at Psych Congress Elevate
Videos
Telehealth Chatbots Promising, but Need Further Research
11/08/2022
Steven Chan, MD, MBA
Steven Chan, MD, MBA, talks research that supports or challenges mental health apps in clinical practice.
Steven Chan, MD, MBA, talks research that supports or challenges mental health apps in clinical practice.
Steven Chan, MD, MBA, talks...
11/08/2022
Psych Congress Network
Dr Steven Chan
Videos
Assess Features and Set Realistic Expectations When Choosing and Using Apps in Clinical Practice
08/08/2022
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses...
08/08/2022
Psych Congress Network
Steven Chan
Videos
How to Evaluate and Integrate Apps Into Treatment With Dr Steven Chan
07/26/2022
Steven Chan, MD, MBA, discusses the ways apps can be integrated into treatment plans and summarizes key elements of the APA's app evaluation model.
Steven Chan, MD, MBA, discusses the ways apps can be integrated into treatment plans and summarizes key elements of the APA's app evaluation model.
Steven Chan, MD, MBA, discusses...
07/26/2022
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
Michael Asbach, DMsc, PA-C
Videos
Differentiating Bipolar II Disorder From Other Psychiatric Conditions
12/08/2025
Michael Asbach, DMSc, PA-C
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach,...
12/08/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC
Videos
Using Digital Tools to Reduce Clinician Burnout
12/03/2025
Desiree Matthews, PHMNP-BC
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych...
12/03/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Comparing Real-World Data on LAIs and Oral Antipsychotics
12/01/2025
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD,...
12/01/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Leveraging Digital Therapeutics for ADHD Management
11/14/2025
Timothy Wilens, MD
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at...
11/14/2025
Psych Congress Network
Jonathan Meyer, MD
Videos
Updated Approaches to Clozapine Monitoring Post-REMS
11/11/2025
Jonathan Meyer, MD
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych...
11/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Avoiding Legal Gray Areas in Cross-State Telepsychiatry
11/04/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress...
11/04/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Navigating Psychiatric Comorbidities in ADHD
10/17/2025
Timothy Wilens, MD
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion,...
10/17/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use